NASDAQ: NEXI - NexImmune, Inc.

Rentabilité sur six mois: -99.96%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions NexImmune, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise NexImmune, Inc.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.

plus de détails
The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2021-02-12
ISIN US65344D1090
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.neximmune.com
Цена ао 0.0001
Changement de prix par jour: 0% (0.0001)
Changement de prix par semaine: 0% (0.0001)
Changement de prix par mois: -99.9% (0.1)
Changement de prix sur 3 mois: -99.95% (0.2089)
Changement de prix sur six mois: -99.96% (0.25)
Changement de prix par an: -100% (5.61)
Evolution du prix sur 3 ans: -100% (2.65)
Evolution des prix depuis le début de l'année: -99.96% (0.232)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0.6519 10
P/E 0 0
EV/EBITDA 0.03 10
Total: 5

Efficacité

Nom Signification Grade
ROA, % -376.36 0
ROE, % -921.57 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0024 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 38.08 5
Rentabilité EPS, % -21.5 0
Total: 3.8
Plus de détails

Établissements Volume Partager, %
Slate Path Capital, LP 37000 0.27
Adage Capital Partners GP L.L.C. 32055 0.23
Allen Operations LLC 25437 0.18
EPIQ Capital Group, LLC 15624 0.11
PNC Financial Services Group, Inc. 12640 0.09
First Manhattan Company 5964 0.04
M28 Capital Management LP 5338 0.04
Geode Capital Management, LLC 4326 0.03
Vanguard Group Inc 3893 0.03
Comerica Bank 3257 0.02



Superviseur Titre d'emploi Paiement Année de naissance
Mr. John Trainer M.B.A. Consultant 1.33M 1974 (51 année)
Dr. Daniel P. Bednarik Senior Vice President of Molecular Engineering & Protein Design N/A
Dr. Robert Douglas Knight M.D. Chief Medical Officer 454.77k 1951 (74 année)
Mr. Chad Rubin Senior Vice President of Corporate Affairs N/A
Dr. Jack A. Ragheb M.D., Ph.D. Senior Vice President of Translational Science N/A
Mr. Matthew Schiller Head of Business Development N/A
Mr. Craig R. Jalbert CIRA President, Treasurer, CS, Principal Executive Officer, Financial Off, & Principal Accounting Off 1962 (63 année)
Ms. Karen Haslbeck Head of Human Resources

Adresse: United States, Gaithersburg. MD, 9119 Gaither Road - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.neximmune.com